7th Sep 2020 09:09
(Alliance News) - AstraZeneca PLC on Monday said new analyses has showed a consistent benefit of Breztri Aerosphere in reducing chronic obstructive pulmonary disease exacerbations across all seasons compared with Bevespi Aerosphere.
Chronic obstructive pulmonary disease is the name for a group of lung conditions that cause breathing difficulties.
A analysis of the Phase III Ethos trial showed a consistent benefit of Breztri Aerosphere - budesonide/glycopyrronium/formoterol fumarate - in reducing the rate of moderate or severe chronic obstructive pulmonary disease exacerbations across all seasons compared with Bevespi Aerosphere - glycopyrronium/formoterol fumarate - in patients with moderate to very severe disease, FTSE 100-listed Astra said.
Ruud Dobber, executive vice president of Astra's BioPharmaceuticals unit, said: "These additional data from the Phase III Ethos trial are important in supporting clinicians' understanding of the robust clinical profile of Breztri Aerosphere, which has been approved in the US, China and Japan and is under regulatory review in the EU."
London-based Astra will present the Phase III Ethos trial data at the European Respiratory Society International Virtual Congress, scheduled to take place from September 7 to 9.
Shares in Astra were up 1.7% at 8,108.26 pence each in London on Monday morning.
By Tapan Panchal; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca